EZH2/PRC2 also has a conserved role in modulating MHC-I antigen presentation, which allows cancer cells to evade immune cells; therefore, EZH2 inhibition or inhibition of embryonic ectoderm development (EED; a reader in the PRC2 complex) (see below; Fig. 1) promotes MHC-I expression and antitumor immunity (Fig. 6A; Burr et al. 2019). Here, EZH2 is linked to cancer.